Evolution Equity Partners has received a $50.8 million commitment from British Patient Capital for their third fund. This specialist technology investor focuses on cybersecurity and enterprise software companies, with previous investments including Quantexa and Panaseer. The UK’s leadership in cybersecurity innovation is highlighted by this investment, which follows a $35 million commitment to Evolution’s second fund in 2020.
Richard Seewald, Founder and Managing Partner at Evolution Equity Partners, expressed excitement about partnering with British Patient Capital and NSSIF to support UK-based cybersecurity companies. The goal is to provide these companies with capital, knowledge, tools, and strategies to drive performance and success in the global market. Seewald emphasized the critical importance of cybersecurity to the safety of UK-based enterprises, governments, and consumers. He highlighted how the current environment underscores the necessity of next-generation technology that can defend and protect society and our way of life.
Robert Greenwood, Investment Director of Funds at British Patient Capital, commented on the evolution of cybersecurity over the last two decades. He stressed how cybersecurity has become a crucial application across all sectors as businesses strive to protect themselves, their customers, and their products. This investment showcases the UK’s leadership in cybersecurity innovation and its expertise in this valuable technology sector. With this new funding commitment from British Patient Capital, Evolution Equity Partners can continue its mission of investing in cutting-edge technology companies that will shape the future of cybersecurity.
